Liquidia Corp (LQDA) Stock Analysis and Metrics

Liquidia

NASDAQ: LQDA

$86.22 ▼ -2.81 (-3.16%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap7.61 Bn

P/E-40.70

P/S26.40

Div. Yield0.00

Revenue Growth (1y) (Qtr)4,158.49

Add ratio to table…

About

Liquidia Corp is a biopharmaceutical company dedicated to improving care for patients with serious respiratory and vascular conditions. The firm concentrates on pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Its lead commercial product YUTREPIA is an inhaled dry powder formulation of treprostinil delivered via a proprietary low effort inhaler. Liquidia also promotes a generic treprostinil injection for parenteral use under a profit sharing arrangement with Sandoz. Beyond marketed products the company advances a liposomal treprostinil candidate L606 designed for less frequent dosing. The core of Liquidia s innovation lies in its PRINT particle engineering platform which creates uniform drug particles to enhance deep lung delivery. The company operates through two wholly owned subsidiaries Liquidia Technologies Inc and Liquidia PAH LLC to separate product development from commercialization activities. Liquidia Technologies Inc handles research formulation manufacturing and early stage clinical studies for all product candidates. Liquidia PAH LLC focuses on commercial promotion sales force management and market access for the injected treprostinil product.

Liquidia derives its primary revenue from the sale of YUTREPIA to patients and healthcare providers in the United States. The product is distributed through specialty pharmacies and is reimbursed by public and private payors. A second revenue stream comes from the promotion agreement with Sandoz under which Liquidia receives a portion of the net profits generated from sales of Treprostinil Injection. The profit share is tiered with fifty percent of net profits up to five hundred million dollars and seventy five percent of net profits above that threshold. After December 31 2028 the profit share reverts to fifty percent if cumulative net profits are below five hundred million dollars and to seventy five percent if cumulative net profits are at or above five hundred million dollars. Additional potential income includes milestone payments and royalties from licensing agreements related to L606 and other pipeline candidates. The company also may receive fees from collaborations that utilize its PRINT technology for non respiratory applications. Liquidia may also earn income from contract manufacturing services for third parties that use its particle engineering platform.

The company operates through the following segments:

• Liquidia Technologies Inc is responsible for research development manufacturing of all product candidates including YUTREPIA and L606 and it applies the PRINT technology to engineer uniform drug particles with precise size and shape for optimal aerosol deposition. The subsidiary oversees formulation development analytical testing and scale up of production processes. It also manages internal quality control and regulatory documentation to support investigational new drug applications and new drug applications.

• Liquidia PAH LLC leads the commercial promotion of Treprostinil Injection in the United States works closely with Sandoz on sales planning pricing and market access and shares in the net profits derived from the product s sales. The subsidiary maintains a dedicated field force that calls on cardiologists pulmonologists and other specialists involved in PAH treatment. It also provides educational resources and reimbursement support to healthcare providers and specialty pharmacies.

Liquidia competes in a specialized segment of the pulmonary hypertension market where inhaled treprostinil therapies are the standard of care for many patients. Principal rivals include United Therapeutics which markets Tyvaso Tyvaso DPI and the infused Remodulin as well as generic versions of these products. Other competitors are Actelion a division of Johnson & Johnson with its nebulized iloprost Ventavis and companies offering oral prostacyclin agonists such as Orenitram and Uptravi. Generic treprostinil injectables from firms like Teva Dr Reddy s Laboratories and Alembic also vie for market share in the parenteral space. Liquidia s differentiation rests on its PRINT technology which enables the production of drug particles that achieve higher lung deposition with lower patient effort compared to existing dry powder inhalers. The company s product YUTREPIA has demonstrated the ability to be titrated to dose levels exceeding those of competing inhaled treprostinil formulations while maintaining a favorable safety profile. Additionally Liquidia benefits from a focused commercial team that targets centers of excellence and high prescribers in the PAH and PHILD communities. The firm s pipeline of liposomal and next generation nebulized candidates further supports its potential to expand beyond current indications and capture additional value in the respiratory disease arena. Liquidia also holds a strong intellectual property portfolio with numerous patents covering its PRINT technology and its drug formulations which provides a barrier to entry for potential competitors. The company s scientific expertise in prostacyclin signaling and its experience with regulatory pathways such as the 505 b 2 route enhance its ability to bring new products to market efficiently.

Liquidia s customers are primarily physicians who specialize in pulmonology cardiology and critical care and who manage patients with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The company also works with specialty pharmacies that dispense its inhaled dry powder product and its injectable treprostinil formulation. In addition Liquidia engages with hospital systems and integrated delivery networks that oversee treatment pathways for these patient populations. Liquidia further interacts with payer organizations including Medicare Medicaid and private insurers to secure coverage and reimbursement for its therapies. Ultimately the patients receiving therapy for these conditions are the end users of Liquidia s products. The firm also collaborates with patient advocacy groups and professional societies to raise awareness about pulmonary hypertension and to support education initiatives for clinicians and caregivers.

Investment Thesis

▲ Bull case

Liquidia Corporation is positioned to capture significant upside from the rapidly expanding PH-ILD market, which management explicitly described as massively underpenetrated despite growing awareness and diagnostic efforts. The company noted that PH-ILD prescriptions now represent approximately 50% of YUTREPIA volume, up from a smaller share at launch, indicating successful penetration into this indication. With an estimated 60,000 PH-ILD patients in the U.S. and recent registry data suggesting 50% to 75% of these patients have a pulmonary hypertension component, the addressable population is substantially larger than currently diagnosed. Management's belief that the PH-ILD opportunity alone exceeds $2 billion to $3 billion in revenue potential, combined with YUTREPIA's differentiated tolerability enabling higher dosing and better outcomes, suggests the drug could become the standard of care in this underserved segment. This is further supported by physician feedback highlighting YUTREPIA's advantages over oral prostacyclins due to reduced gastrointestinal toxicity and direct lung delivery, which is driving real-world switching behavior even without formal mandates.
The company's self-funded growth model, fueled entirely by operating cash flow, represents a structural advantage that reduces financial risk and enables sustained reinvestment into commercial, clinical, and manufacturing expansions. Liquidia ended Q1 FY26 with $222.8 million in cash, up $32.1 million year-to-date, despite funding North Carolina manufacturing expansion and sales force growth. This internal financing capability allows the company to avoid dilution or debt burdens while advancing multiple catalysts: the ASCENT Cohort B study transitioning patients from Tyvaso DPI to YUTREPIA, the pivotal Phase III RESPIRE study of L606 in PH-ILD, and early-stage programs targeting IPF, PPF, PH-COPD, and scleroderma-associated Raynaud's. Management emphasized that all these initiatives are being funded from operating cash flow rather than capital markets—a rarity in the biotech sector at this commercial stage. This financial self-sufficiency not only de-risks the pipeline but also signals confidence in the sustainability of current profitability, which is expected to grow alongside rising income tax expense as a recurring component of financial performance.
Liquidia's market share gains in the inhaled prostacyclin category reflect a fundamental shift in physician preference driven by YUTREPIA's superior product profile, not temporary market tailwinds. The company grew its share from 10% in Q3 FY25 to nearly 23% in Q1 FY26 while the total market expanded only 5% in both quarters, indicating Liquidia captured virtually all market growth. This outperformance is supported by increasing prescription depth—physicians prescribing YUTREPIA to five or more patients rose 25% since February to 270—and a pull-through rate of approximately 85%, which management called extraordinarily good. The shift is further validated by anecdotal physician feedback describing a 'night and day difference' in tolerability and dosing flexibility compared to legacy therapies, particularly regarding cough reduction and the ability to titrate to higher doses without systemic side effects. These factors suggest YUTREPIA is becoming the anchored inhaled therapy in PAH and PH-ILD, with switching trends from oral prostacyclins and parenteral pump therapy accelerating as clinicians recognize its advantages in combination regimens, including with sotatercept.

Liquidia Corporation is positioned to capture significant upside from the rapidly expanding PH-ILD market, which management explicitly described as massively underpenetrated despite growing awareness and diagnostic efforts. The company noted that PH-ILD prescriptions now represent approximately 50% of YUTREPIA volume, up from a smaller share at launch, indicating successful penetration into this indication. With an estimated 60,000 PH-ILD patients in the U.S. and recent registry data suggesting 50% to 75% of these patients have a pulmonary hypertension component, the addressable population is substantially larger than currently diagnosed. Management's belief that the PH-ILD opportunity alone exceeds $2 billion to $3 billion in revenue potential, combined with YUTREPIA's differentiated tolerability enabling higher dosing and better outcomes, suggests the drug could become the standard of care in this underserved segment. This is further supported by physician feedback highlighting YUTREPIA's advantages over oral prostacyclins due to reduced gastrointestinal toxicity and direct lung delivery, which is driving real-world switching behavior even without formal mandates.
The company's self-funded growth model, fueled entirely by operating cash flow, represents a structural advantage that reduces financial risk and enables sustained reinvestment into commercial, clinical, and manufacturing expansions. Liquidia ended Q1 FY26 with $222.8 million in cash, up $32.1 million year-to-date, despite funding North Carolina manufacturing expansion and sales force growth. This internal financing capability allows the company to avoid dilution or debt burdens while advancing multiple catalysts: the ASCENT Cohort B study transitioning patients from Tyvaso DPI to YUTREPIA, the pivotal Phase III RESPIRE study of L606 in PH-ILD, and early-stage programs targeting IPF, PPF, PH-COPD, and scleroderma-associated Raynaud's. Management emphasized that all these initiatives are being funded from operating cash flow rather than capital markets—a rarity in the biotech sector at this commercial stage. This financial self-sufficiency not only de-risks the pipeline but also signals confidence in the sustainability of current profitability, which is expected to grow alongside rising income tax expense as a recurring component of financial performance.
Liquidia's market share gains in the inhaled prostacyclin category reflect a fundamental shift in physician preference driven by YUTREPIA's superior product profile, not temporary market tailwinds. The company grew its share from 10% in Q3 FY25 to nearly 23% in Q1 FY26 while the total market expanded only 5% in both quarters, indicating Liquidia captured virtually all market growth. This outperformance is supported by increasing prescription depth—physicians prescribing YUTREPIA to five or more patients rose 25% since February to 270—and a pull-through rate of approximately 85%, which management called extraordinarily good. The shift is further validated by anecdotal physician feedback describing a 'night and day difference' in tolerability and dosing flexibility compared to legacy therapies, particularly regarding cough reduction and the ability to titrate to higher doses without systemic side effects. These factors suggest YUTREPIA is becoming the anchored inhaled therapy in PAH and PH-ILD, with switching trends from oral prostacyclins and parenteral pump therapy accelerating as clinicians recognize its advantages in combination regimens, including with sotatercept.

▼ Bear case

Liquidia Corporation faces significant execution risk in its pipeline expansion efforts, particularly regarding the clinical and regulatory viability of L606 and broader indication programs, which may not deliver the anticipated differentiation or success rates implied by management. While the RESPIRE Phase III study of L606 in PH-ILD is actively screening patients, the open-label Phase II data showed a median achievable dose of 229 micrograms, and there remains uncertainty about whether twice-daily dosing can maintain stable pharmacokinetics across 24 hours—a critical factor for once-daily adherence and nighttime symptom control. Rajeev Saggar acknowledged that the jury is still out on dosing expectations for L606, and the company's reliance on an 'enriched for success' study design for future programs like PH-COPD introduces potential bias that may not reflect real-world effectiveness. Furthermore, the timeline for these initiatives is lengthy, with PH-COPD studies not expected to begin until 2027 at best, meaning near-term growth remains heavily dependent on YUTREPIA's performance in PAH and PH-ILD, which could plateau if competitive responses intensify or if real-world tolerability issues emerge beyond the controlled clinical settings highlighted in testimonials.
The company's optimistic $1 billion net revenue target for 2027 may be predicated on aggressive market share assumptions and opportunity sizing that overestimates the speed of adoption in underpenetrated markets like PH-ILD and PH-COPD, particularly given persistent diagnostic and referral gaps. Management cited a potential $6 billion revenue opportunity across PAH and PH-ILD alone, assuming inhaled treprostinil captures value proportional to oral prostacyclin markets, but this conflates distinct pathophysiologies and treatment paradigms. While awareness efforts are increasing, Scott Moomaw acknowledged that many community pulmonologists still do not routinely consider PH in ILD patients, focusing instead on antifibrotics without assessing for pulmonary hypertension. The reliance on sales force expansion to drive diagnosis and referral creates a slow, resource-intensive growth engine that may not scale quickly enough to support the implied uptake rates. Additionally, the assumption that YUTREPIA can displace entrenched therapies like oral selexipag or parenteral pumps in combination with sotatercept overlooks inertia in prescribing habits, reimbursement hurdles, and the need for robust real-world evidence to justify formulary access and guideline inclusion—factors that could delay adoption beyond management's projections.
Liquidia's increasing profitability and income tax expense, while a sign of success, may signal the onset of margin pressures as the company scales, particularly if ongoing investments in manufacturing, sales force, and clinical programs begin to outweigh revenue growth. Although Q1 FY26 showed strong operating leverage—net income rose 262% sequentially to $52.9 million on 44% revenue growth—the sustainability of this trajectory is uncertain given the capital-intensive nature of expanding North Carolina manufacturing capacity and funding multiple clinical trials from operating cash flow. The company acknowledged it is now recording recurring income tax expense, which will reduce net earnings as pretax income grows, and there is no indication of margin expansion beyond current levels. If growth in prescriptions and patient starts decelerates—as Roger Jeffs cautioned against forecasting acceleration—while fixed and semi-fixed costs continue to rise from commercial and infrastructure investments, operating leverage could reverse, leading to stagnating or declining profitability despite top-line growth. This risk is amplified by the lack of discussion around gross margin trends, pricing power, or rebate pressures in a market where competitors may respond with discounts or enhanced patient support programs to counter Liquidia's share gains.

Liquidia Corporation faces significant execution risk in its pipeline expansion efforts, particularly regarding the clinical and regulatory viability of L606 and broader indication programs, which may not deliver the anticipated differentiation or success rates implied by management. While the RESPIRE Phase III study of L606 in PH-ILD is actively screening patients, the open-label Phase II data showed a median achievable dose of 229 micrograms, and there remains uncertainty about whether twice-daily dosing can maintain stable pharmacokinetics across 24 hours—a critical factor for once-daily adherence and nighttime symptom control. Rajeev Saggar acknowledged that the jury is still out on dosing expectations for L606, and the company's reliance on an 'enriched for success' study design for future programs like PH-COPD introduces potential bias that may not reflect real-world effectiveness. Furthermore, the timeline for these initiatives is lengthy, with PH-COPD studies not expected to begin until 2027 at best, meaning near-term growth remains heavily dependent on YUTREPIA's performance in PAH and PH-ILD, which could plateau if competitive responses intensify or if real-world tolerability issues emerge beyond the controlled clinical settings highlighted in testimonials.
The company's optimistic $1 billion net revenue target for 2027 may be predicated on aggressive market share assumptions and opportunity sizing that overestimates the speed of adoption in underpenetrated markets like PH-ILD and PH-COPD, particularly given persistent diagnostic and referral gaps. Management cited a potential $6 billion revenue opportunity across PAH and PH-ILD alone, assuming inhaled treprostinil captures value proportional to oral prostacyclin markets, but this conflates distinct pathophysiologies and treatment paradigms. While awareness efforts are increasing, Scott Moomaw acknowledged that many community pulmonologists still do not routinely consider PH in ILD patients, focusing instead on antifibrotics without assessing for pulmonary hypertension. The reliance on sales force expansion to drive diagnosis and referral creates a slow, resource-intensive growth engine that may not scale quickly enough to support the implied uptake rates. Additionally, the assumption that YUTREPIA can displace entrenched therapies like oral selexipag or parenteral pumps in combination with sotatercept overlooks inertia in prescribing habits, reimbursement hurdles, and the need for robust real-world evidence to justify formulary access and guideline inclusion—factors that could delay adoption beyond management's projections.
Liquidia's increasing profitability and income tax expense, while a sign of success, may signal the onset of margin pressures as the company scales, particularly if ongoing investments in manufacturing, sales force, and clinical programs begin to outweigh revenue growth. Although Q1 FY26 showed strong operating leverage—net income rose 262% sequentially to $52.9 million on 44% revenue growth—the sustainability of this trajectory is uncertain given the capital-intensive nature of expanding North Carolina manufacturing capacity and funding multiple clinical trials from operating cash flow. The company acknowledged it is now recording recurring income tax expense, which will reduce net earnings as pretax income grows, and there is no indication of margin expansion beyond current levels. If growth in prescriptions and patient starts decelerates—as Roger Jeffs cautioned against forecasting acceleration—while fixed and semi-fixed costs continue to rise from commercial and infrastructure investments, operating leverage could reverse, leading to stagnating or declining profitability despite top-line growth. This risk is amplified by the lack of discussion around gross margin trends, pricing power, or rebate pressures in a market where competitors may respond with discounts or enhanced patient support programs to counter Liquidia's share gains.

Segments Breakdown of Revenue (2025)

Peer Comparison

Companies in the Drug Manufacturers - Specialty & Generic

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	HLN	Haleon plc	88.07 Bn	103.29	6.00	11.45 Bn
2	TEVA	Teva Pharmaceutical Industries Ltd	35.75 Bn	23.02	2.06	16.63 Bn
3	ZTS	Zoetis Inc.	31.84 Bn	12.05	3.35	9.05 Bn
4	TAK	Takeda Pharmaceutical Co Ltd	27.18 Bn	-10.29	0.59	28.76 Bn
5	UTHR	UNITED THERAPEUTICS Corp	23.09 Bn	17.93	7.28	-
6	RDHL	RedHill Biopharma Ltd.	21.32 Bn	2,931.66	2.24	-
7	VTRS	Viatris Inc	19.96 Bn	-67.32	1.37	14.34 Bn
8	NBIX	Neurocrine Biosciences Inc	17.66 Bn	26.41	5.69	-

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password